Join us for this informative seminar, HFSA Heart Failure Seminar: What You Need to Know STAT! HF Stats, where leading experts delve into the latest trends and statistics on heart failure. This session is designed to provide the recent insights on heart failure incidence, mortality, hospitalizations, and treatment. Attendees will also gain a comprehensive understanding of the strategies HFSA is employing to address these trends and close critical gaps in care.

 The content in this Seminar draws on the HFSA HF Stats Report, an annual report that seeks to fill the gap in data and statistical analysis on the depth and breadth of heart failure and its impact on the health systems in the U.S. In addition to highlighting key findings, HFStats.org offers resources to help you interpret and share the data, including infographics, fact sheets, and downloadable statistics. Similar to the American Heart Association’s Heart Disease and Stroke Statistical Update, HF Stats is the go-to resource for the most up-to-date statistics on heart failure.

This activity is intended for cardiologists, interventional cardiologists, primary care physicians, cardiac surgeons, internists, nurse practitioners, physician assistants, nurses, pharmacists, researchers, industry professionals, and other stakeholders involved in the care of patients with heart failure.

At the conclusion of this activity, learners will be better able to: 

• Describe major changes and trends in the incidence and prevalence of heart failure.
• Highlight changes in mortality rates related to heart failure.
• Compare and contrast recent trends in hospitalizations and treatment approaches for heart failure.
• Outline the strategies HFSA is implementing to address these current trends based on the latest statistics

Faculty

• Biykem Bozkurt, MD, PhD, FHFSA
• Robert L. Page II, PharmD, BCPS, FHFSA
• Coleen McIlvennan, PhD, DNP, ANP, FHFSA
• Eileen Hsich, MD, FHFSA
• Michael Felker, MD, FHFSA
• Cynthia Chauhan, Patient

 Program Planners

• Biykem Bozkurt, MD, PhD, FHFSA
• Robert L. Page II, PharmD, BCPS, FHFSA

Faculty Disclosures

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24-months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity. Speakers will have a disclosure slide at the beginning of each presentation. All potential   conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.
 
The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:

• Eileen Hsich
• Coleen McIlvennan
• Robert L. Page II
• Shauna Wheeler (CE Review)

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:

• Biykem Bozkurt – Advisory Panel: ABIOMED, AstraZeneca, Bayer AG, Boehringer Ingelheim, Medtronic, Merck, American Regent (Ended), Amgen (Ended), Baxter (Ended), Sanofi-Aventis (Ended), scPharmaceuticals (Ended); Steering Committee: Renovacor, Respicardia, Vifor Pharma; Clinical End Points Committee: Abbott Laboratories (Ended); Data Safety Monitoring Board: Cardurion Pharmaceuticals (Ended), LivaNova (Ended)
• Michael Felker – Consultant: Abbott Laboratories, American Regent, Arena Pharmaceuticals, Bristol-Myers Squibb, Cytokinetics, GlaxoSmithKline, Medtronic, Novartis, Reprieve Cardiovascular, Rocket Pharmaceuticals, Sequana Medical, LivaNova (Ended); Research Support: Bayer AG, CSL Behring, Merck, Amgen (Ended)
• Rhonda Monroe – Advisory Panel: CVRx (Ended), 4TEEN4 (Ended); Consultant: Roche, Boehringer Ingelheim (Ended), Merck (Ended)

Off-Label Disclosure
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this educational activity for a maximum of 1.50 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  Successful completion of this CME activity, includes participation in the evaluation component.

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America.  This activity is approved for a maximum of 1.50 contact hours.

The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This educational activity is accredited for up to 1.50 contact hours of knowledge-based CPE.  ACPE Universal Activity Numbers (UAN): JA4008267-0000-24-014-L01-P (live attendance only); JA4008267-0000-24-018-H01-P (on-demand/home study)

The Heart Failure Society of America has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Learners should claim only the credit commensurate with the extent of their participation in the activity.